Evolus (NASDAQ:EOLS) vs. Smith & Nephew SNATS (NYSE:SNN) Head-To-Head Analysis

Evolus (NASDAQ:EOLS) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Evolus and Smith & Nephew SNATS, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1	1	4	0	2.50
Smith & Nephew SNATS	0	4	1	1	2.50

Evolus currently has a consensus price target of $16.00, suggesting a potential upside of 159.32%. Smith & Nephew SNATS has a consensus price target of $30.93, suggesting a potential upside of 5.17%. Given Evolus’ higher probable upside, equities analysts clearly believe Evolus is more favorable than Smith & Nephew SNATS.

Volatility & Risk

Evolus has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Smith & Nephew SNATS has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Earnings and Valuation

This table compares Evolus and Smith & Nephew SNATS”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18 million	1.37	-$51.64 million	($0.67)	-9.21
Smith & Nephew SNATS	$6.16 billion	2.04	$625.00 million	N/A	N/A

Smith & Nephew SNATS has higher revenue and earnings than Evolus.

Insider and Institutional Ownership

90.7% of Evolus shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 5.0% of Evolus shares are held by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Evolus and Smith & Nephew SNATS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
Smith & Nephew SNATS	N/A	N/A	N/A

Summary

Smith & Nephew SNATS beats Evolus on 6 of the 11 factors compared between the two stocks.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.